Roche pulls out of alliance with Basilea for new antibiotic

July 2004
PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p17
Market Research Report
Reports on the strategic alliance of Roche Pharmaceutical Co. with Basilea Pharmaceutica Ltd. for the development of new antibiotic drug. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for pharmaceutical biotechnology industry.


Related Articles

  • MDRNA signs licensing agreement with Roche.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p18 

    The article reports on the signing of a licensing agreement by MDRNA Inc. and Roche Pharmaceuticals. The licensing agreement is consistent to which Roche will get a non-exclusive license to a portion of MDRNA's technology platform for the development of ribonucleic acid interference-based...

  • Roche and Maxygen in Interferon Deal. Krause, Carey // Chemical Market Reporter;6/2/2003, Vol. 263 Issue 22, p11 

    Reports that Roche Holding AG has signed a multi-million agreement with Maxygen Inc. to license its next generation interferons to treat hepatitis. Terms of the strategic deal; Benefits of the agreement for both companies; Expectations from Roche's hepatitis portfolio in 2004; Drugs in...

  • Roche Expands Memory Pact.  // Chemical Market Reporter;9/22/2003, Vol. 264 Issue 9, p2 

    Reports on the strategic alliance between pharmaceutical firm Roche Pharmaceuticals and Memory Pharmaceuticals Corp. Benefits of the alliance for the companies; Terms of the partnership; Development of a central nervous system drug by the companies.

  • BioInvent Tumbles on Double Blow to ThromboGenics Deal. Sheridan, Cormac // BioWorld International;6/6/2012, Vol. 17 Issue 23, p1 

    The article reports on setbacks suffered by the strategic alliance between BioInvent International AB and ThromboGenics NV in 2012. The two companies decided to stop development of an anticoagulation antibody, TB-402, after they received unfavorable data from a Phase IIb head-to-head trial...

  • Roche Spins Off Unites Into Biotech Company. Milmo, Sean // Chemical Market Reporter;10/23/2000, Vol. 258 Issue 17, p8 

    Focuses on the decision of Roche to spin off its research and development segment into a biotech company to be named Basilea. Plan for Basilea.

  • Alliances Update.  // PharmaWatch: Biotechnology;Aug2006, Vol. 5 Issue 8, p13 

    The article offers news brief on biotechnology industries strategic partnership. Roche AG and Evotec OAI AG have formed an alliance inorder to discover inhibitors in the treatment of diseases. Vertex Pharmaceuticals Inc. and Janssen Pharmaceutica NV have agreed to join forces for the development...

  • OSI / Genentech / Roche: a breakthrough for EGFR inhibitor.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p4 

    Reports on the collaboration between OSI Pharmaceuticals Inc., Genentech Inc., and Roche Pharmaceutical Co. for the phase III clinical trial of Tarceva for the non-small cell lung cancer. Benefits of the agreement for both parties involved; Number of patients involved in the study; Response of...

  • Dalcetrapib.  // Drugs in R&D;2010, Vol. 10 Issue 1, p33 

    Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This review discusses the development history and scientific...

  • ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.  // Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5 

    Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics